0001856420-21-000001.txt : 20210420 0001856420-21-000001.hdr.sgml : 20210420 20210419191520 ACCESSION NUMBER: 0001856420-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210420 DATE AS OF CHANGE: 20210419 EFFECTIVENESS DATE: 20210420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Goldilocks Therapeutics, Inc. CENTRAL INDEX KEY: 0001856420 IRS NUMBER: 825080202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-396368 FILM NUMBER: 21835852 BUSINESS ADDRESS: STREET 1: 55 E. FIELD DRIVE CITY: BEDFORD STATE: NY ZIP: 10506 BUSINESS PHONE: (914) 205-3862 MAIL ADDRESS: STREET 1: 55 E. FIELD DRIVE CITY: BEDFORD STATE: NY ZIP: 10506 D 1 primary_doc.xml X0708 D LIVE 0001856420 Goldilocks Therapeutics, Inc. 55 E. FIELD DRIVE BEDFORD NY NEW YORK 10506 (914) 205-3862 DELAWARE None None Corporation true 2018 Arthur Klausner 55 E. Field Drive Bedford NY NEW YORK 10506 Executive Officer Director Krishna Polu 55 E. Field Drive Bedford NY NEW YORK 10506 Director Scott Minick 55 E. Field Drive Bedford NY NEW YORK 10506 Director Biotechnology Decline to Disclose 06b false 2019-12-11 false true true true true Convertible notes and the securities into which the notes are convertible (and the securities into which the securities issued upon conversion of the notes are convertible) false 0 1230883 1230883 0 false 23 0 0 0 false Goldilocks Therapeutics, Inc. Arthur Klausner Arthur Klausner President and CEO 2021-04-19